SUPPLEMENTARY INFORMATION: Title: OMB Control No. 0917–0036, Fast Track Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery: IHS Customer Service Satisfaction and Similar Surveys.

Abstract: The IHS will be engaging in information collection activities that will garner qualitative customer and stakeholder feedback in an efficient, timely manner, in accordance with the Administration’s commitment to improving service delivery within Federal Agencies. Qualitative feedback is information that provides useful insights on perceptions and opinions, but are not statistical surveys that yield quantitative results that can be generalized to the population of study. This feedback will provide insight into customer or stakeholder perceptions, opinions, experiences and expectations, and provide an early warning of issues with service. Also, the collection of qualitative feedback will assist IHS to focus its attention on areas where communication, training, or changes in operations might improve delivery of products or services. These collections will allow for ongoing, collaborative and actionable communications between the Agency and its customers and stakeholders. Furthermore, the collection activity will allow feedback to contribute directly to the improvement of program management.

Feedback or information collected under this generic clearance will provide useful information, but it will not yield data that can be generalized to the overall population. This type of generic clearance for qualitative collection will not be used for quantitative information collections that are designed to yield reliably actionable results, such as monitoring trends over time or documenting program performance. Such data uses require more rigorous designs that address: the target population to which generalizations will be made, sampling frame, sample design (including stratification and clustering), precision requirements or power calculations that justify the proposed sample size, the expected response rate, methods for assessing potential non-response bias, protocols for data collection, and any testing procedures that were or will be undertaken prior fielding the study. Depending on the degree of influence the results are likely to have, such collections may still be eligible for submission for other generic mechanisms that are designed to yield quantitative results. Below are the IHS projected average estimates for the next three years: Current Actions: Extension of approval for a collection of information.

**Type of Review:** Extension.

**Affected Public:** Individuals and households, businesses and organizations, and Tribal Government.

**Average expected annual number of activities:**
- **Respondents:** 105,000.
- **Annual responses:** 105,000.
- **Frequency of response:** Once per request.

**Average minutes per response:** 10.

**Burdens hours:** 17,500.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

**Dated:** November 17, 2017.

Michael D. Weahkee,
Assistant Surgeon General, U.S. Public Health Service, Acting Director, Indian Health Service.

[FR Doc. 2017–25815 Filed 11–29–17; 8:45 am]

BILLING CODE 4165–16–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**National Cancer Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; NCI SPORE I Review.

**Date:** January 25–26, 2018.

**Time:** 4:00 p.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Cambria Hotel & Suite Rockville, 1 Helen Heneghan Way, Rockville, MD 20850.

**Contact Person:** David G. Ransom, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W124, Bethesda, MD 20892–9750, 240–276–6351, david.ransom@nih.gov.

**Name of Committee:** National Cancer Institute Initial Review Group; Subcommittee F—Institutional Training and Education.

**Date:** February 26–27, 2018.

**Time:** 7:00 p.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

**Contact Person:** Timothy C. Meeker, MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W642, Bethesda, MD 20892–9750, 240–276–6464, meekert@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

**Dated:** November 24, 2017.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–25785 Filed 11–29–17; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**National Institute on Drug Abuse; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; NCI SPORE I Review.

**Date:** January 25–26, 2018.

**Time:** 4:00 p.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Cambria Hotel & Suite Rockville, 1 Helen Heneghan Way, Rockville, MD 20850.

**Contact Person:** David G. Ransom, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W124, Bethesda, MD 20892–9750, 240–276–6351, david.ransom@nih.gov.

**Name of Committee:** National Cancer Institute Initial Review Group; Subcommittee F—Institutional Training and Education.

**Date:** February 26–27, 2018.

**Time:** 7:00 p.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

**Contact Person:** Timothy C. Meeker, MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W642, Bethesda, MD 20892–9750, 240–276–6464, meekert@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

**Dated:** November 24, 2017.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–25785 Filed 11–29–17; 8:45 am]

BILLING CODE 4140–01–P